Get the Stockscreener App
22.59
0.38%
+0.065
Arrowhead Pharmaceuticals Inc. stock is currently priced at $22.59, with a 24-hour trading volume of 660.00K.
It has seen a +0.38% increased in the last 24 hours and a -19.63% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $23.02 pivot point. If it approaches the $21.98 support level, significant changes may occur.
Arrowhead Pharmaceuticals Inc. Stock (ARWR) Financials Data
Arrowhead Pharmaceuticals Inc. (ARWR) Revenue 2024
ARWR reported a revenue (TTM) of $181.74 million for the quarter ending December 31, 2023, a -34.71% decline year-over-year.
Arrowhead Pharmaceuticals Inc. (ARWR) Net Income 2024
ARWR net income (TTM) was -$296.81 million for the quarter ending December 31, 2023, a -92.09% decrease year-over-year.
Arrowhead Pharmaceuticals Inc. (ARWR) Cash Flow 2024
ARWR recorded a free cash flow (TTM) of -$402.70 million for the quarter ending December 31, 2023, a -70.45% decrease year-over-year.
Arrowhead Pharmaceuticals Inc. (ARWR) Earnings per Share 2024
ARWR earnings per share (TTM) was -$2.77 for the quarter ending December 31, 2023, a -88.44% decline year-over-year.
Arrowhead Pharmaceuticals Inc. Stock (ARWR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lu Hongbo | Director |
Mar 20 '24 |
Buy |
27.50 |
1,000 |
27,500 |
33,680 |
| Lu Hongbo | Director |
Mar 19 '24 |
Buy |
28.00 |
1,000 |
28,000 |
32,680 |
| Lu Hongbo | Director |
Mar 18 '24 |
Buy |
27.49 |
1,000 |
27,490 |
31,680 |
| Myszkowski Kenneth Allen | Chief Financial Officer |
Mar 06 '24 |
Sale |
35.19 |
40,000 |
1,407,600 |
400,600 |
| Anzalone Christopher Richard | Chief Executive Officer |
Jan 31 '24 |
Option Exercise |
14.54 |
57,499 |
836,035 |
3,772,547 |
| Anzalone Christopher Richard | Chief Executive Officer |
Jan 31 '24 |
Sale |
32.35 |
57,499 |
1,860,019 |
3,715,048 |
| Hamilton James C | Chief Discovery/Trans Medicine |
Jan 12 '24 |
Sale |
36.89 |
7,940 |
292,904 |
210,851 |
| Vakiener Victoria | Director |
Jan 11 '24 |
Sale |
38.10 |
4,720 |
179,813 |
32,001 |
| Waddill William D. | Director |
Jan 11 '24 |
Sale |
38.07 |
3,934 |
149,759 |
47,870 |
| Ferrari Mauro | Director |
Jan 11 '24 |
Sale |
38.06 |
3,147 |
119,787 |
60,778 |
Arrowhead Pharmaceuticals Inc. Stock (ARWR) Latest News
NetApp, Zoom Video And 2 Other Stocks Insiders Are Selling
Benzinga
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
Benzinga
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
Benzinga
Cracking The Code: Understanding Analyst Reviews For Arrowhead Pharma
Benzinga
Lamb Weston Posts Upbeat Results, Joins Omega Therapeutics, Allstate And Other Big Stocks Moving Higher On Thursday
Benzinga
Why SoFi Technologies Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
About Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its medicines include ARO-HBV, a Phase I/II subcutaneous ribonucleic acid interference(RNAi) therapy candidate that is used for the treatment of chronic hepatitis B viral infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc.; and Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
COMPANY PROFILE
NameArrowhead Pharmaceuticals Inc.
SectorHealthcare (1198)
IndustryBiotechnology (689)
Web
Phone626-304-3400
Employee93
Twitter
@ArrowheadPharma
SEC filings
Latest SEC Filings
Next earning date2024-04-30
Address225 South Lake Avenue, Suite 1050, Pasadena, CA, United States (91101)
0.77%
0.44%
Cap:
|
Volume (24h):